Table of Contents
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Sexually Transmitted Disease Testing Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. High Prevalence & Rise in Incidences of STD across the Globe
3.2.1.2. Implementation of National Screening Programs
3.2.1.3. Supporting Reimbursement of STDs Testing
3.2.2. Restraints
3.2.2.1. Social Stigma Associated with Patients Visiting Specialized STD Clinics
3.2.2.2. Huge Protection of Patients Infected with STDs in Remotes Areas
3.2.3. Opportunities
3.2.3.1. Decrease In Number of Visits to Government Clinics
3.2.3.2. National Screening Programs Across the Globe
3.2.3.3. Niche Opportunities for Technology and POC Test Providers in an Emerging Economy
3.2.4. Challenges
3.2.4.1. Stringent Regulations
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Sexually Transmitted Disease Testing Market Overview
4.1. Market Size & Forecast by Value, 2019-2029
4.1.1. By Value (USD Million)
4.2. Market Share & Forecast
4.2.1. By Disease
4.2.1.1. Chlamydia
4.2.1.2. Syphilis
4.2.1.3. Gonorrhoea
4.2.1.4. Hyper Simplex Virus
4.2.1.5. Human Immunodeficiency Virus
4.2.1.6. Chancroid
4.2.1.7. Others
4.2.2. By Location
4.2.2.1. Laboratory
4.2.2.1.1. Commercial/Private Labs
4.2.2.1.2. Public Health Labs
4.2.2.2. Point of Care (POC)
4.2.3. By Device
4.2.3.1. Laboratory Devices
4.2.3.1.1. Thermal Cyclers PCR
4.2.3.1.2. Lateral Flow Readers- Immune Chromatographic Arrays
4.2.3.1.3. Flow Cytometers
4.2.3.1.4. Differential Light Scattering Machines
4.2.3.1.5. Absorbance Micro Plate Reader- Enzyme- Linked Immunosorbent Assay (ELISA)
4.2.3.1.6. Others
4.2.3.2. Point of Care (POC) Devices
4.2.4. By Region
4.2.4.1. North America
4.2.4.2. Europe
4.2.4.3. Asia Pacific
4.2.4.4. Latin America
4.2.4.5. Middle East and Africa
5. North America Sexually Transmitted Disease Testing Market
5.1. Market Size & Forecast by Value, 2019-2029
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Disease
5.2.2. By Location
5.2.3. By Device
5.2.4. By Country
5.2.4.1. US
5.2.4.1.1. By Disease
5.2.4.1.2. By Location
5.2.4.1.3. By Device
5.2.4.2. Canada
5.2.4.2.1. By Disease
5.2.4.2.2. By Location
5.2.4.2.3. By Device
6. Europe Sexually Transmitted Disease Testing Market
6.1. Market Size & Forecast by Value, 2019-2029
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Disease
6.2.2. By Location
6.2.3. By Device
6.2.4. By Country
6.2.4.1. Germany
6.2.4.1.1. By Disease
6.2.4.1.2. By Location
6.2.4.1.3. By Device
6.2.4.2. UK
6.2.4.2.1. By Disease
6.2.4.2.2. By Location
6.2.4.2.3. By Device
6.2.4.3. Italy
6.2.4.3.1. By Disease
6.2.4.3.2. By Location
6.2.4.3.3. By Device
6.2.4.4. France
6.2.4.4.1. By Disease
6.2.4.4.2. By Location
6.2.4.4.3. By Device
6.2.4.5. Spain
6.2.4.5.1. By Disease
6.2.4.5.2. By Location
6.2.4.5.3. By Device
6.2.4.6. The Netherlands
6.2.4.6.1. By Disease
6.2.4.6.2. By Location
6.2.4.6.3. By Device
6.2.4.7. Rest of Europe
6.2.4.7.1. By Disease
6.2.4.7.2. By Location
6.2.4.7.3. By Device
7. Asia-Pacific Sexually Transmitted Disease Testing Market
7.1. Market Size & Forecast by Value, 2019-2029
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Disease
7.2.2. By Location
7.2.3. By Device
7.2.4. By Country
7.2.4.1. China
7.2.4.1.1. By Disease
7.2.4.1.2. By Location
7.2.4.1.3. By Device
7.2.4.2. India
7.2.4.2.1. By Disease
7.2.4.2.2. By Location
7.2.4.2.3. By Device
7.2.4.3. Japan
7.2.4.3.1. By Disease
7.2.4.3.2. By Location
7.2.4.3.3. By Device
7.2.4.4. South Korea
7.2.4.4.1. By Disease
7.2.4.4.2. By Location
7.2.4.4.3. By Device
7.2.4.5. Australia & New Zealand
7.2.4.5.1. By Disease
7.2.4.5.2. By Location
7.2.4.5.3. By Device
7.2.4.6. Indonesia
7.2.4.6.1. By Disease
7.2.4.6.2. By Location
7.2.4.6.3. By Device
7.2.4.7. Malaysia
7.2.4.7.1. By Disease
7.2.4.7.2. By Location
7.2.4.7.3. By Device
7.2.4.8. Singapore
7.2.4.8.1. By Disease
7.2.4.8.2. By Location
7.2.4.8.3. By Device
7.2.4.9. Philippines
7.2.4.9.1. By Disease
7.2.4.9.2. By Location
7.2.4.9.3. By Device
7.2.4.10. Vietnam
7.2.4.10.1. By Disease
7.2.4.10.2. By Location
7.2.4.10.3. By Device
7.2.4.11. Rest of APAC
7.2.4.11.1. By Disease
7.2.4.11.2. By Location
7.2.4.11.3. By Device
8. Latin America Sexually Transmitted Disease Testing Market
8.1. Market Size & Forecast by Value, 2019-2029
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Disease
8.2.2. By Location
8.2.3. By Device
8.2.4. By Country
8.2.4.1. Brazil
8.2.4.1.1. By Disease
8.2.4.1.2. By Location
8.2.4.1.3. By Device
8.2.4.2. Mexico
8.2.4.2.1. By Disease
8.2.4.2.2. By Location
8.2.4.2.3. By Device
8.2.4.3. Argentina
8.2.4.3.1. By Disease
8.2.4.3.2. By Location
8.2.4.3.3. By Device
8.2.4.4. Peru
8.2.4.4.1. By Disease
8.2.4.4.2. By Location
8.2.4.4.3. By Device
8.2.4.5. Colombia
8.2.4.5.1. By Disease
8.2.4.5.2. By Location
8.2.4.5.3. By Device
8.2.4.6. Rest of LATAM
8.2.4.6.1. By Disease
8.2.4.6.2. By Location
8.2.4.6.3. By Device
9. Middle East & Africa Sexually Transmitted Disease Testing Market
9.1. Market Size & Forecast by Value, 2019-2029
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Disease
9.2.2. By Location
9.2.3. By Device
9.2.4. By Country
9.2.4.1. Saudi Arabia
9.2.4.1.1. By Disease
9.2.4.1.2. By Location
9.2.4.1.3. By Device
9.2.4.2. UAE
9.2.4.2.1. By Disease
9.2.4.2.2. By Location
9.2.4.2.3. By Device
9.2.4.3. Qatar
9.2.4.3.1. By Disease
9.2.4.3.2. By Location
9.2.4.3.3. By Device
9.2.4.4. Kuwait
9.2.4.4.1. By Disease
9.2.4.4.2. By Location
9.2.4.4.3. By Device
9.2.4.5. South Africa
9.2.4.5.1. By Disease
9.2.4.5.2. By Location
9.2.4.5.3. By Device
9.2.4.6. Nigeria
9.2.4.6.1. By Disease
9.2.4.6.2. By Location
9.2.4.6.3. By Device
9.2.4.7. Algeria
9.2.4.7.1. By Disease
9.2.4.7.2. By Location
9.2.4.7.3. By Device
9.2.4.8. Rest of MEA
9.2.4.8.1. By Disease
9.2.4.8.2. By Location
9.2.4.8.3. By Device
10. Competitive Landscape
10.1. List of Key Players and Their Offerings
10.2. Global Sexually Transmitted Disease Testing Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Sexually Transmitted Disease Testing Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
12.1. Abbott Laboratories
12.2. BioMerieux, Inc.
12.3. Becton Dickinson Company
12.4. Danaher Corporation
12.5. Bio-Rad Laboratories, Inc.
12.6. Hologic, Inc.
12.7. Diasorin Molecular LLC
12.8. Roche Holding AG
12.9. Orasure Technologies, Inc.,
12.10. Thermo Fisher Scientific Inc.
12.11. AccuBioTech Co. Ltd.
12.12. AdvaCare Pharma
12.13. BIOGENIX Inc. Pvt. Ltd.
12.14. CTK Biotech Inc.
12.15. Everlywell Inc.
12.16. F. Hoffmann La Roche Ltd.
12.17. Gilead Sciences Inc.
12.18. GlaxoSmithKline Plc
12.19. Merck and Co. Inc.
12.20. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumption & Limitation